Drug Profile


Alternative Names: G-2Me-PE; Glycyl-2-methyl-L-prolyl-L-glutamic acid; Glycyl-L-2-methylprolyl-L-glutamic acid; NNZ-2566

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Neuren Pharmaceuticals
  • Developer Neuren Pharmaceuticals;; Walter Reed Army Institute of Research
  • Class Glutamates; Neuropeptides; Neuroprotectants; Oligopeptides; Pyrrolidines; Small molecules
  • Mechanism of Action Cytokine inhibitors; Glial cell modulators; Neuropeptide receptor modulators; Synaptic transmission modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Fragile X syndrome; Rett syndrome
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Brain injuries; Fragile X syndrome; Rett syndrome
  • Preclinical Multiple sclerosis
  • No development reported Autistic disorder

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Autistic-disorder in Australia (PO, Liquid)
  • 31 May 2017 Neuren receives patent for trofinetide in the US for Fragile X syndrome and in Europe for Autistic disorders including Rett syndrome and Fragile X syndrome
  • 31 May 2017 Neuren has composition of matter patent protection for trofinetide in Europe
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top